Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (2093)	10/4/1997 12:50:00 PM
From: JOHN W.	of 6136

Note: I accurately predicted that after the very questionable downgrade by Alex Brorn after last earning release (that blew away his estimates), he would return to a strong buy just prior to the next release. Crossen will soon have to return to strong buy as we get dangerously close to European Approval. Not that 40% of Crixivan sales are outside of the U.S. What makes anyone think that Viracept will not do the same thing outside of the U.S. as they have stolen so much from Crix here. Roche is apparently taking actions to launch "their new drug-VIRACEPT" in Europe this year. Roche is the strongest international marketing partner that this little little company could have. Roche is definitely in a win-win situation with Agouron, not only Viracept but more importantly Roches dominance in the new Cancer drugs the two companies will bring to mkt. P.S. SHORT?: watch out for phase I results of AG3340, you never know when they might appear.....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next